Engineering Bispecific Antibody Targets for Novel Arsenal in Immune Therapy - SABPA 2022

Nicholas Joseph Abuid, Ph.D. Application Scientist. ACROBiosystems.

Nicholas Abuid is the West Coast Field Application Scientist for ACROBiosystems. He is a trained biomedical engineer whose doctor focus was Type I Diabetes Cell Therapy. At ACROBiosystems, Nicholas is working with leaders in both industry and academia to support their research needs. Nicholas is part of a team that helps to guide in the use and development of recombinant proteins that can be used for COVID-19, CAR T-cell therapy, as well as many other immune and auto-immune conditions. As a member of ACRO, he is highly interested in leveraging the company’s resources and state-of-the-art technology to help our partners and clients develop next-generation therapies.

Talk Abstract: Bispecific antibodies refer to a large family of molecules that recognize two different epitopes or antigens. There has been rising interest in therapeutic applications of these dual-target functionality antibodies. The potential of bispecific antibodies in precisely targeting immune cells with synergistic therapeutic effect on tumor cells stands out among antibody therapeutics in tumor immunotherapy. Bispecific antibodies can bind to two different sites, blocking two separate signaling pathways, enhancing cancer cell cytotoxicity, and reducing drug resistance caused by tumor pathway activation. After binding to two different cell surface antigens, the binding specificity increases. A well-known bispecific antibody target is CD3, which stabilizes T cell receptor structure and induces activating signals. This talk will cover ACROBiosystems’ efforts to engineer and evaluate homogenous CD3 proteins to accelerate the research and development of bispecific antibodies. In addition, our collaborators efforts in bispecific antibody advances will be reviewed.